Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Fn14

  • Diego Martin-Sanchez
  • Miguel Fontecha-Barriuso
  • Maria D. Sanchez-Niño
  • Maria C. Izquierdo
  • Alvaro C. Ucero
  • Alberto Ortiz
  • Ana B. Sanz
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_594

Synonyms

Background

Fibroblast growth factor–inducible-14 (Fn14) was described in fibroblasts as an immediate-early response gene to growth factors. Fn14 is a member of the TNF receptor superfamily (TNFRSF), also termed TNFRSF12A. The only ligand for Fn14 is the cytokine TWEAK (Wiley and Winkles 2003), and Fn14 is the only signaling receptor for TWEAK. Both have been targeted therapeutically in humans.

Structure

Phylogenetically Fn14 is much conserved and there is a 90% homology between the mouse and the human protein (Wiley and Winkles 2003). The human Fn14 gene is located at chromosomal position 16p13.3, encodes a type I transmembrane protein of 129 aa that is processed into a mature 102-aa protein, and is the smallest member of the TNFRSF (Wiley and Winkles 2003). The extracellular domain (53-aa) contains a cysteine-rich domain typical of TNFRSF members, required for the interaction with TWEAK (He et al. 2009). Conversely, the Tyr176 residue of TWEAK is key for TWEAK-Fn14 binding and can be chemically targeted (Dhruv et al. 2013). The intracellular domain (29-aa) is the shortest of TNFRSF members, contains TNFR-associated factor (TRAF)-binding sites, but lacks a death domain (DD), thus differing from many TNFRSF members (Wiley and Winkles 2003). Fn14 has two putative threonine phosphorylation sites in the cytoplasmic domain that may play a role in the Fn14-TRAF association (Fig. 1).
Fn14, Fig. 1

Structural features of human Fn14. Fn14 is a 129-aa type I transmembrane protein that is processed by signal peptidase into a mature 102-aa receptor. TRAF BS TRAF-binding sites, T threonine-phosphorylation sites

Alternative splicing generates a smaller isoform of Fn14 which lacks the extracellular, TWEAK-binding domain (Brown et al. 2013).

Expression

Fn14 is expressed at low level in numerous cell types and tissues, including diverse epithelial cells, endothelial cells, vascular cells, and fibroblasts (Burkly et al. 2007). However, Fn14 is strongly upregulated in response to stress or injury triggered by factors such as cytokines, growth factors, and toxins (Sanz et al. 2016). Moreover, Fn14 is upregulated during tissue regeneration in liver, kidney, pancreas, and skeletal muscle (Karaca et al. 2014; Sanz et al. 2009; Enwere et al. 2014; Wu et al. 2013).

In silico, the Fn14 promoter contains consensus sequences for various transcription factors, but only SP1 and AP1 showed DNA-binding activity and were involved in Fn14 upregulation in denervated skeletal muscle (Tajrishi et al. 2014b). The Fn14 promoter also contains a functional retinoic acid receptor (RAR) site, and RAR signaling mediates Fn14 expression in hepatocellular carcinoma (Wang et al. 2012). The Fn14 promoter also contains a CpG island close to the transcription start site, and expression is also regulated by DNA methylation. Methylation of CpG islands by DNA methyltransferases (Dnmts) leads to gene silencing. Dnmt3 downregulation in denervated muscle leads to Fn14 promoter hypomethylation and Fn14 overexpression (Tajrishi et al. 2014b).

Fn14 is also regulated at the posttranslational level. Similar to other members of the TNFRSF, Fn14 interaction with TWEAK leads to receptor internalization and degradation. However, Fn14 also undergoes rapid and constitutive turnover independent of TWEAK (Gurunathan et al. 2014). This data has physiological relevance since changes in Fn14 trafficking could lead to Fn14 stabilization and increase TWEAK-Fn14 binding and signaling. Soluble Fn14 (sFn14) is increased in plasma and urine of mouse models of kidney diseases and in patients with diabetic nephropathy. However, the mechanism that generates sFn14 is unknown. It may depend on receptor shedding since this is common in the TNFR family. The role of sFn14 is also unidentified; there are two hypotheses: it may inhibit TWEAK actions as a decoy receptor or preserve circulating TWEAK, thus increasing TWEAK activity. Further studies are necessary to understand the generation and the role of sFn14 (Sharif et al. 2016).

Signaling

Upon TWEAK binding, the Fn14 TRAF-binding domain associates with TRAFs 1, 2, 3, and 5, activating various MAPKs, including MAP3K14, as well as Ras, PI3K/Akt, JAK2-STAT, and the canonical and noncanonical pathways for NFκB activation (Brown et al. 2003; Ortiz et al. 2017; Ucero et al. 2013a, b). TWEAK independent-Fn14 signaling might occur when Fn14 levels are very high, although this has not been tested directly (Winkles 2008). In this regard, overexpression of the alternative spliced Fn14 isoform lacking the extracellular domain resulted in NFκB activation, indicating that TWEAK-independent Fn14 signaling does occur (Brown et al. 2013). This information may help design better therapeutic approaches against the TWEAK/Fn14 axis.

TWEAK/Fn14 signaling may also recruit EGFR and FGFR-1 signaling pathways.

In tubular epithelial cells, the TWEAK/Fn14 interaction induces EGFR transactivation by activating the ADAM17 sheddase and thus promoting the release of membrane-bound EGFR ligands. TWEAK/Fn14-induced EGFR transactivation mediates inflammatory responses to TWEAK dependent of MAPKs, whereas it did not affect TWEAK-induced NFκB activation (Rayego-Mateos et al. 2013). Moreover, a positive correlation between Fn14 expression and EGFR activation was observed in lung cancer (Whitsett et al. 2012).

There is a physical interaction between Fn14 and FGFR-1 that is increased by their respective ligands TWEAK and FGF-1 (Novoyatleva et al. 2014). Thus, in cardiomyocytes Fn14 and FGFR-1 act synergistically to promote cell cycle reentry.

Biological Activity

Proliferation: Regeneration and Fibrosis

Fn14 activation by TWEAK induces proliferation in different cell types, including endothelial, epithelial, tumor, progenitor cells, and keratinocytes (Cheng et al. 2016; Novoyatleva et al. 2010; Sanz et al. 2009; Tirnitz-Parker et al. 2010; Winkles 2008). However, Fn14-induced proliferation may have different consequences, such as regeneration, fibrosis, tumor progression, or inflammation, depending on cell type, tissue, or pathology (Fig. 2).
Fn14, Fig. 2

Fn14-induced intracellular signaling pathways and biological activity. Upon activation by TWEAK, Fn14 activates different signaling cascades, such as MAPKs, Ras, PI3K/Akt, JAK2-STAT, and the canonical and noncanonical pathways for NFκB activation. The activated pathways may differ between the different cellular types. The biological processes promoted by Fn14 in each cell type depend on the intracellular signaling activated and the cell environment and may include cell death, inflammation, proliferation, and fibrosis. Activation of these processes has physiological consequences

Fn14-mediated proliferation may be beneficial and contribute to liver, pancreas, and kidney regeneration following surgical mass reduction (Karaca et al. 2014; Sanz et al. 2009; Wu et al. 2013). After partial hepatectomy, Fn14 expression is increased, and TWEAK/Fn14 signaling promotes hepatocyte and hepatic progenitor cells proliferation (Karaca et al. 2014). A similar result were observed after partial pancreatectomy, since Fn14 deficiency delays pancreatic regeneration and impairs β-cell neogenesis from ductal epithelium (Wu et al. 2013), and in the remnant kidney following unilateral nephrectomy, where TWEAK deficiency impaired and exogenous TWEAK promoted tubular cell proliferation (Sanz et al. 2009). Thus, Fn14 activation could have beneficial effects after noninflammatory loss of liver, kidney, or pancreatic mass.

However, sustained activation of Fn14 may induce fibroblast proliferation and promotes fibrosis, as is observed in kidneys, liver, heart, and muscle. In kidneys, Fn14 activation induces fibroblast proliferation, leading to more severe experimental renal fibrosis in a model of sustained renal injury (Ucero et al. 2013a). Fn14 is also upregulated in liver myofibroblats from patients with fatty liver disease (Wilhelm et al. 2016). Moreover, in the heart, Fn14 activation induces cardiac fibroblast proliferation and myofibroblast differentiation, while Fn14 deletion reduces myocardial fibrosis in experimental heart failure (Ucero et al. 2013a). The molecular pathways involved in Fn14-induced fibrosis include NFκB, RhoA, TGF-β, and Ras/ERK pathway (Chen et al. 2012, 2015; Novoyatleva et al. 2013; Ucero et al. 2013a).

Cell Death

Fn14 activation can also promote cell death. Indeed, TWEAK was named for its capacity to induce apoptosis in interferon γ-treated HT29 adenocarcinoma cells (Chicheportiche et al. 1997). TWEAK also promotes death in neurons, monocytes, tumor cell lines, resident renal cells, and others, but this usually requires Fn14 upregulation driven by proinflammatory stimuli (Michaelson and Burkly 2009; Ortiz et al. 2009). Usually, Fn14 has been related with apoptosis, but in recent years it was also shown to promote necroptosis (Linkermann et al. 2013).

As an example, in an inflammatory medium, Fn14 promotes apoptosis in renal tubular cells. In this context, caspase inhibition prevents features of apoptosis but does not prevent overall cell death (Justo et al. 2006). Indeed, caspase inhibition increases oxidative stress-dependent cell death. However, necrostatin-1, a small molecule inhibitor of necroptosis, prevents this form of cell death suggesting that Fn14 may under certain conditions promote necroptosis (Linkermann et al. 2013). In this regard, TWEAK/Fn14 blockade prevented cell death in different models of tissue injury, such as experimental acute kidney injury or cerebral ischemia (Sanz et al. 2016). The capacity of Fn14 to induce cell death in tumor cells has become a strategy for cancer treatment.

Inflammation

Fn14 has proinflammatory actions in numerous cell types and tissues and this is mediated mainly by the canonical NFκB pathway. However, MAPKs including MAP3K14, the noncanonical NFκB pathway, JAK2/STAT and EGFR transactivation may mediate TWEAK/Fn14 inflammatory response (Ortiz et al. 2017; Rayego-Mateos et al. 2013; Ucero et al. 2013b; Valiño-Rivas et al. 2016). Fn14 activation can also induce the expression of molecules that amplify the inflammatory response, such as CXCL16 and HMGB1. Thus, in renal tubular cells CXCL16 increased inflammatory response of TWEAK (Izquierdo et al. 2012). In macrophages, Fn14 may promote M1 macrophages differentiation throughout HMGB1 release (Moreno et al. 2013).

Independently of the intracellular pathways involved, Fn14-induced inflammation has a pathophysiological relevance, since targeting TWEAK/Fn14 reduces inflammatory responses in experimental models including systemic lupus erythematosus (SLE) and lupus nephritis, acute colitis, acute kidney injury, and proteinuric kidney disease (Doerner et al. 2016; Dohi et al. 2014; Sanchez-Niño et al. 2013; Xia et al. 2014).

Reduction of Tissue and Cell Protective Factors

In addition to promoting an NFκB-mediated proinflammatory response, TWEAK/Fn14 also recruit the canonical NFκB pathway and epigenetic mechanisms such as histone deacetylases (HDAC) to repress the expression of genes with protective functions, such as Klotho, an antiaging hormone, and PGC-1α, a key mitochondrial biogenesis regulator (Moreno et al. 2011), (Ruiz-Andres et al. 2016). Both genes, Klotho and PGC-1α, have nephroprotective properties and Fn14 represses their expression in vivo during inflammatory renal diseases.

Studies in Experimental Models and Human Diseases

The biological processes mediated by TWEAK/Fn14 described above suggest that this system may have a pathophysiological relevance in disease conditions in which these processes play a key role. In this regard, functional experimental studies and descriptive human approaches have characterized the role of TWEAK/Fn14 in disease.

Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)

SLE is a multisystem autoimmune disease featuring autoantibody production, with involvement of kidneys (lupus nephritis), skin inflammation, and neuropsychiatric disease, among others. Functional experimental in vivo studies suggest the involvement of Fn14 in these manifestations (Zhao 2007). Functional in vivo studies disclosed a role of Fn14 in nephritis in the chronic graft-vs-host model of SLE but this model may not reflect well the human disease. The role of Fn14 was confirmed in spontaneous murine lupus nephritis in MRL/lpr mice. In this model, Fn14 deficiency in renal cells preserved renal function and reduced proteinuria, inflammation, and glomerular deposition of IgG, but circulating autoantibodies were not reduced (Xia et al. 2014). Fn14-Fc treatment also reduced glomerulonephritis and renal tubular damage in SLE model using sanroque mice (Min et al. 2016). However, Fn14 targeting reduced circulating antibodies in sanroque mice, contrary to the observation in MRL/lpr Fn14-KO mice (Xia et al. 2014; Zhao et al. 2007; Min et al. 2016). Thus, the effect of TWEAK/Fn14 on the immune response is controversial in mice and merits detailed studies in humans.

MRL/lpr Fn14-KO mice have significantly attenuated skin disease and markedly fewer skin infiltrating macrophages and T cells, comparing with MRL/lpr-WT mice Doerner et al. 2015, 2016). Interestingly, ultraviolet-B irradiation, a trigger for lupus skim manifestations, increased Fn14 levels in vitro and in vivo, and TWEK/Fn14 induced an inflammatory response in keratinocytes (Doerner et al. 2015).

The TWEAK/Fn14 system could also play a role in neuropsychiatric disease associated to SLE. Depressive-like behavior is an early manifestation of SLE that improved in MRL/lpr Fn14-KO mice compared with WT mice. Moreover, Fn14 deficiency also improved cognition in MRL/lpr mice (Wen et al. 2013). In this regard, Fn14 deficiency decreased the expression of proinflammatory mediators and the antibodies deposition in brain and improved blood-brain barrier integrity (Wen et al. 2013, 2015).

Collectively, these data suggest that TWEAK/Fn14 plays an important role in the pathogenesis of lupus and could be a therapeutic target. However, a randomized clinical trial of neutralizing anti-TWEAK antibodies as add-on, nephroprotective therapy on top of immune suppressants for lupus nephropathy failed to meet its primary end-point (ClinicalTrials.gov, Identifier:NCT01499355).

Rheumatoid Arthritis

Rheumatoid arthritis is an autoimmune disease characterized by chronic joint inflammation that leads to cartilage and bone destruction. Human joint cells, such as synoviocytes, chondrocytes, and osteoblasts, express Fn14 and release inflammatory mediators in response to TWEAK (Burkly et al. 2007). Moreover, Fn14 expression is increased in synovial tissue of human rheumatoid arthritis and Fn14 activation induces proliferation and inflammation in synovial cell isolated from these patients (Burkly et al. 2007; Kamijo et al. 2008; van Kuijk et al. 2010). A phase I clinical trial of neutralizing anti-TWEAK antibodies in rheumatoid arthritis disclosed downmodulation of circulating inflammatory biomarkers (Wisniacki et al. 2013) (ClinicalTrials.gov, Identifier:NCT00771329). However, resources were shifted to address the therapeutic potential of TWEAK targeting in lupus nephropathy and clinical development was halted.

Cancer

Fn14 is highly expressed in several tumors, including colorectal cancer, pancreatic carcinoma, non–small cell lung cancer, and ovarian cancer (Culp et al. 2010; Dai et al. 2009; Whitsett et al. 2012). Fn14 activation may favor tumor growth by promoting angiogenesis, cell survival, migration, and proliferation in some tumor cells. However, Fn14 also induces cell death in various tumor cells; indeed, the lethal effect of Fn14 is higher in tumor cells than in normal cells. In this regard, strategies under study to target the TWEAK/Fn14 axis in cancer are aimed at promoting tumor cell death. A humanized agonistic anti-Fn14 antibody, BIIB036, mimics many of the activities of TWEAK. BIIB036 induced tumor cell death in vitro, tumor regression in multiple xenograft models and in patient-derived primary tumors grown in mice, and had antimetastatic activity (Michaelson et al. 2011, 2012). Moreover, BIIB036 enhanced the efficacy of a variety of standard chemotherapeutics without added toxicity in xenograft models (Michaelson et al. 2012). Another agonistic humanized anti-Fn14 antibody, PDL192, shares some properties with BIIB036, and is in phase I safety study in patients with solid tumors (ClinicalTrials.gov, Identifier: NCT00738764). The antitumor activity of both antibodies is mainly mediated by antibody-dependent cellular cytotoxicity (ADCC) and activation of NF-κB signaling (Culp et al. 2010; Purcell et al. 2014; Zhou et al. 2013a). Fn14-targeted immunotoxins and granzyme B-anti-Fn14 constructs also showed antitumor effect in different xenograft models of cancer (Zhou et al. 2013a, b, 2014).

By contrast, a humanized anti-TWEAK neutralizing antibody, RG7212, blocked TWEAK-induced signaling and cytokine production, induced apoptosis, and inhibited tumor growth without toxicity in mice (Yin et al. 2013). A phase I clinical trial in patients with advanced solid tumors expressing Fn14 demonstrated that RG7212 was well tolerated and depleted TWEAK. In one patient, the tumor regressed (ClinicalTrials.gov, Identifier: NCT01383733). However, high exposures to RG7212 and high-tumor Fn14 might be required for the antitumor effect of TWEAK targeting (Meulendijks et al. 2016). Thus, the efficacy of anti-TWEAK treatment depends, in part, on the Fn14 levels.

Fn14 may be also a prognostic marker for cancer. Fn14 expression is upregulated in several tumor types and in some cases correlates with tumor progression. In human prostate cancer, Fn14 expression is negative in normal prostate epithelium, mildly positive in high-grade prostatic intraepithelial neoplasia foci, and very positive in prostate adenocarcinoma and correlates with poor clinical outcome (Huang et al. 2011; Sanz et al. 2012). Moreover, higher Fn14 expression in gastric cancer was associated with shorter survival and higher levels of the antiapoptotic protein BclxL (Kwon et al. 2012). In addition, bioinformatics analysis of metastatic tissues disclosed that Fn14 predicted brain metastasis progression in breast cancer patients (Martínez-Aranda et al. 2015).

Muscle Atrophy

Skeletal muscle atrophy or wasting is a major human morbidity associated to aging, chronic diseases, and inactivity/disuse conditions (Tajrishi et al. 2014c). Skeletal muscle atrophy is the result of either enhanced protein degradation or reduced synthesis or both. The TWEAK/Fn14 system is a major regulator of skeletal muscle mass (Tajrishi et al. 2014c). Fn14 expression is low in healthy skeletal muscle but increases under catabolic condition such as denervation (Mittal et al. 2010; Tajrishi et al. 2014b) amplifying TWEAK-induced NFκB activation and the degradation of specific muscle proteins (Mittal et al. 2010). Changes in the mitochondrial content can also promote muscle wasting. In this sense, Fn14 repressed PGC-1α expression and reduced the mitochondrial content, while PGC-1α overexpression blocked TWEAK-induced atrophy and reduced Fn14 expression.

The Fn14/TWEAK system has also been implicated in muscle atrophy associated to aging, myotonic dystrophy type 1 (DM1), and cancer-induced cachexia. Fn14-KO mice showed less inflammation, increased level of specific muscle proteins, and reduced levels of ubiquitinated proteins in skeletal muscle during aging than WT mice (Tajrishi et al. 2014a). Fn14 expression is upregulated in muscle tissue from DM1 patients and Fn14-KO mice showed better preserved skeletal muscle in experimental DM1 (Yadava et al. 2015). Cachexia is a metabolic disorder that includes progressive muscle wasting and is frequent in terminal stages of chronic diseases as cancer. Fn14 antagonistic antibodies prevented tumor-associated cachexia (Johnston et al. 2015).

Collectively, this data indicate that targeting the Fn14/TWEAK axis could be beneficial in muscle atrophy. Indeed, phase I clinical trials are studying BIIB023 neutralizing anti-TWEAK antibodies in patients with muscle atrophy and healthy male volunteers (Sanz et al. 2016) (ClinicalTrials.gov, Identifier:NCT01943513).

Vascular and Non-immune Renal Diseases

Accumulating evidences support a role for Fn14 in the pathogenesis of acute and chronic renal diseases since Fn14 on intrinsic renal cells, including podocytes, tubular cells, and renal fibroblasts, may facilitate inflammation, cell death, and fibrosis and decrease nephroprotective factors in culture and in vivo (Moreno et al. 2011; Ruiz-Andres et al. 2016; Sanz et al. 2014b, 2016). Targeting the TWEAK/Fn14 pathway protected from different forms of experimental acute kidney injury (Sanz et al. 2016) decreased glomerular inflammation in experimental nonimmune proteinuria (Sanchez-Niño et al. 2013; Valiño-Rivas et al. 2016) and decreased kidney fibrosis and inflammation in unilateral ureteral obstruction.

Chronic kidney disease progression may lead to end-stage kidney disease, requiring dialysis. Peritoneal dialysis uses the peritoneal membrane to clear waste products but peritonitis is a relatively common complication. In this regard, Fn14 expression was upregulated in peritoneal biopsies from peritoneal dialysis patients and correlated with mesothelial injury, fibrosis, and inflammation. Moreover, TWEAK administration induces peritoneal inflammation in mice (Sanz et al. 2014a).

Chronic kidney disease is associated with cardiovascular disease, particularly atherosclerosis and vascular calcification, which constitute the major causes of morbidity and mortality (Hénaut et al. 2016a). Fn14 can mediate renal and vascular injury associated to hyperlipidemia through proinflammatory cytokine production and macrophage recruitment (Muñoz-García et al. 2009). Furthermore, new mediators of Fn14-induced vascular damage have been described, such as Nox-2 and HMGB1 (Madrigal-Matute et al. 2015; Moreno et al. 2013). TWEAK activation of Fn14 promotes phosphate-induced human vascular smooth muscle cell calcification by favoring their osteogenic transition and increasing MMP9 activity through NFκB activation (Hénaut et al. 2016b). TWEAK/Fn14 also contributes to abdominal aortic aneurysms and Fn14-KO mice were protected from experimental aneurysms induced by elastase perfusion (Tarín et al. 2014).

Collectively, these data suggest that Fn14 could be a therapeutic target in both kidney and vascular disease.

Regardless the role of Fn14 in renal and vascular injury, Fn14 could be a potential biomarker of renal injury, as soluble sFn14 has been detected increased in urine and plasma of mice models of renal diseases and in patients where sFn14 levels correlates with disease severity (Sharif et al. 2016).

Summary

Fn14 is the only receptor for TWEAK, a cytokine of the TNF superfamily. Both are broadly expressed and may regulate cell proliferation, cell death, cell differentiation, and inflammation. The pathways activated by TWEAK/Fn14 signaling include alternative and classic NFκB, MAPKs, and PI3K/Akt pathway. Fn14 lacks the DD domain, characteristic of the TNFR superfamily, but signals through TRAF-binding domains. In vivo, Fn14 expression in healthy tissues is usually low but is significantly upregulated after injury. Functional studies targeting TWEAK and or Fn14 implicate the system in promoting acute and chronic tissue injury and in modulating cancer biology. Fn14 activation can also contribute to tissue repair and any therapeutic intervention should consider this possibility. Clinical targeting of TWEAK/Fn14 has proved safe in phase 1 and phase 2 studies. Development of the neutralizing anti-TWEAK antibody, BIIB023, for lupus nephritis is no longer pursued because of futility while PDL192 anti-Fn14 antibodies in subjects with advanced solid tumors (ClinicalTrials.gov, Identifier: NCT01499355, NCT00738764).

References

  1. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J. 2003;371:395–403.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Brown SA, Cheng E, Williams MS, Winkles JA. TWEAK-independent Fn14 self-association and NF-κB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain. PLoS One. 2013;8:e65248.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine. 2007;40:1–16.PubMedCrossRefGoogle Scholar
  4. Chen HN, Wang DJ, Ren MY, Wang QL, Sui SJ. TWEAK/Fn14 promotes the proliferation and collagen synthesis of rat cardiac fibroblasts via the NF-кB pathway. Mol Biol Rep. 2012;39:8231–41.PubMedCrossRefGoogle Scholar
  5. Chen S, Liu J, Yang M, Lai W, Ye L, Chen J, Hou X, Ding H, Zhang W, Wu Y, et al. Fn14, a downstream target of the TGF-β signaling pathway, regulates fibroblast activation. PLoS One. 2015;10:e0143802.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Cheng H, Xu M, Liu X, Zou X, Zhan N, Xia Y. TWEAK/Fn14 activation induces keratinocyte proliferation under psoriatic inflammation. Exp Dermatol. 2016;25:32–7.PubMedCrossRefGoogle Scholar
  7. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem. 1997;272:32401–10.PubMedCrossRefGoogle Scholar
  8. Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, Su M, Sho M, Steinle R, Wong MH, et al. Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res. 2010;16:497–508.PubMedCrossRefGoogle Scholar
  9. Dai L, Gu L, Ding C, Qiu L, Di W. TWEAK promotes ovarian cancer cell metastasis via NF-kappaB pathway activation and VEGF expression. Cancer Lett. 2009;283:159–67.PubMedCrossRefGoogle Scholar
  10. Dhruv H, Loftus JC, Narang P, Petit JL, Fameree M, Burton J, Tchegho G, Chow D, Yin H, Al-Abed Y, et al. Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis. J Biol Chem. 2013;288:32261–76.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Doerner JL, Wen J, Xia Y, Paz KB, Schairer D, Wu L, Chalmers SA, Izmirly P, Michaelson JS, Burkly LC, et al. TWEAK/Fn14 signaling involvement in the pathogenesis of cutaneous disease in the MRL/lpr model of spontaneous lupus. J Invest Dermatol. 2015;135:1986–95.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Doerner J, Chalmers SA, Friedman A, Putterman C. Fn14 deficiency protects lupus-prone mice from histological lupus erythematosus-like skin inflammation induced by ultraviolet light. Exp Dermatol. 2016;25(12):969–76.Google Scholar
  13. Dohi T, Kawashima R, Kawamura YI, Otsubo T, Hagiwara T, Amatucci A, Michaelson J, Burkly LC. Pathological activation of canonical nuclear-factor κB by synergy of tumor necrosis factor α and TNF-like weak inducer of apoptosis in mouse acute colitis. Cytokine. 2014;69:14–21.PubMedCrossRefGoogle Scholar
  14. Enwere EK, Lacasse EC, Adam NJ, Korneluk RG. Role of the TWEAK-Fn14-cIAP1-NF-κB signaling axis in the regulation of myogenesis and muscle homeostasis. Front Immunol. 2014;5:34.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Gurunathan S, Winkles JA, Ghosh S, Hayden MS. Regulation of fibroblast growth factor-inducible 14 (Fn14) expression levels via ligand-independent lysosomal degradation. J Biol Chem. 2014;289:12976–88.PubMedPubMedCentralCrossRefGoogle Scholar
  16. He F, Dang W, Saito K, Watanabe S, Kobayashi N, Güntert P, Kigawa T, Tanaka A, Muto Y, Yokoyama S. Solution structure of the cysteine-rich domain in Fn14, a member of the tumor necrosis factor receptor superfamily. Protein Sci. 2009;18:650–6.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Hénaut L, Sanchez-Nino MD, Aldamiz-Echevarría Castillo G, Sanz AB, Ortiz A. Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification. Expert Opin Ther Targets. 2016a;20:89–105.PubMedCrossRefGoogle Scholar
  18. Hénaut L, Sanz AB, Martin-Sanchez D, Carrasco S, Villa-Bellosta R, Aldamiz-Echevarria G, Massy ZA, Sanchez-Nino MD, Ortiz A. TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NFκB. Cell Death Dis. 2016b;7:e2305.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Huang M, Narita S, Tsuchiya N, Ma Z, Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, et al. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome. Carcinogenesis. 2011;32:1589–96.PubMedCrossRefGoogle Scholar
  20. Izquierdo MC, Sanz AB, Mezzano S, Blanco J, Carrasco S, Sanchez-Niño MD, Benito-Martín A, Ruiz-Ortega M, Egido J, Ortiz A. TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. Kidney Int. 2012;81:1098–107.PubMedCrossRefGoogle Scholar
  21. Johnston AJ, Murphy KT, Jenkinson L, Laine D, Emmrich K, Faou P, Weston R, Jayatilleke KM, Schloegel J, Talbo G, et al. Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival. Cell. 2015;162:1365–78.PubMedCrossRefGoogle Scholar
  22. Justo P, Sanz AB, Sanchez-Niño MD, Winkles JA, Lorz C, Egido J, Ortiz A. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int. 2006;70:1750–8.PubMedCrossRefGoogle Scholar
  23. Kamijo S, Nakajima A, Kamata K, Kurosawa H, Yagita H, Okumura K. Involvement of TWEAK/Fn14 interaction in the synovial inflammation of RA. Rheumatology (Oxford). 2008;47:442–50.CrossRefGoogle Scholar
  24. Karaca G, Swiderska-Syn M, Xie G, Syn WK, Krüger L, Machado MV, Garman K, Choi SS, Michelotti GA, Burkly LC, et al. TWEAK/Fn14 signaling is required for liver regeneration after partial hepatectomy in mice. PLoS One. 2014;9:e83987.PubMedPubMedCentralCrossRefGoogle Scholar
  25. Kwon OH, Park SJ, Kang TW, Kim M, Kim JH, Noh SM, Song KS, Yoo HS, Wang Y, Pocalyko D, et al. Elevated fibroblast growth factor-inducible 14 expression promotes gastric cancer growth via nuclear factor-κB and is associated with poor patient outcome. Cancer Lett. 2012;314:73–81.PubMedCrossRefGoogle Scholar
  26. Linkermann A, Bräsen JH, Darding M, Jin MK, Sanz AB, Heller JO, De Zen F, Weinlich R, Ortiz A, Walczak H, et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2013;110:12024–9.PubMedPubMedCentralCrossRefGoogle Scholar
  27. Madrigal-Matute J, Fernandez-Laso V, Sastre C, Llamas-Granda P, Egido J, Martin-Ventura JL, Zalba G, Blanco-Colio LM. TWEAK/Fn14 interaction promotes oxidative stress through NADPH oxidase activation in macrophages. Cardiovasc Res. 2015;108:139–47.PubMedCrossRefGoogle Scholar
  28. Martínez-Aranda A, Hernández V, Guney E, Muixí L, Foj R, Baixeras N, Cuadras D, Moreno V, Urruticoechea A, Gil M, et al. FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies. Oncotarget. 2015;6:44254–73.PubMedPubMedCentralCrossRefGoogle Scholar
  29. Meulendijks D, Lassen UN, Siu LL, Huitema AD, Karanikas V, Mau-Sorensen M, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, et al. Exposure and tumor Fn14 expression as determinants of pharmacodynamics of the anti-TWEAK monoclonal antibody RG7212 in patients with Fn14-positive solid tumors. Clin Cancer Res. 2016;22:858–67.PubMedCrossRefGoogle Scholar
  30. Michaelson JS, Burkly LC. Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. Results Probl Cell Differ. 2009;49:145–60.PubMedCrossRefGoogle Scholar
  31. Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, Day ES, Berquist L, Cho S, Li Y, Parr M, et al. Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs. 2011;3:362–75.PubMedPubMedCentralCrossRefGoogle Scholar
  32. Michaelson JS, Kelly R, Yang L, Zhang X, Wortham K, Joseph IB. The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models. Cancer Biol Ther. 2012;13:812–21.PubMedCrossRefGoogle Scholar
  33. Min HK, Kim SM, Park JS, Byun JK, Lee J, Kwok SK, Park YW, Cho ML, Park SH. Fn14-Fc suppresses germinal center formation and pathogenic B cells in a lupus mouse model via inhibition of the TWEAK/Fn14 pathway. J Transl Med. 2016;14:98.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Mittal A, Bhatnagar S, Kumar A, Lach-Trifilieff E, Wauters S, Li H, Makonchuk DY, Glass DJ. The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol. 2010;188:833–49.PubMedPubMedCentralCrossRefGoogle Scholar
  35. Moreno JA, Izquierdo MC, Sanchez-Niño MD, Suárez-Alvarez B, Lopez-Larrea C, Jakubowski A, Blanco J, Ramirez R, Selgas R, Ruiz-Ortega M, et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. J Am Soc Nephrol. 2011;22:1315–25.PubMedPubMedCentralCrossRefGoogle Scholar
  36. Moreno JA, Sastre C, Madrigal-Matute J, Muñoz-García B, Ortega L, Burkly LC, Egido J, Martín-Ventura JL, Blanco-Colio LM. HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes. Arterioscler Thromb Vasc Biol. 2013;33:612–20.PubMedCrossRefGoogle Scholar
  37. Muñoz-García B, Moreno JA, López-Franco O, Sanz AB, Martín-Ventura JL, Blanco J, Jakubowski A, Burkly LC, Ortiz A, Egido J, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 2009;29:2061–8.PubMedCrossRefGoogle Scholar
  38. Novoyatleva T, Diehl F, van Amerongen MJ, Patra C, Ferrazzi F, Bellazzi R, Engel FB. TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc Res. 2010;85:681–90.PubMedCrossRefGoogle Scholar
  39. Novoyatleva T, Schymura Y, Janssen W, Strobl F, Swiercz JM, Patra C, Posern G, Wietelmann A, Zheng TS, Schermuly RT, et al. Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction. Basic Res Cardiol. 2013;108:325.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Novoyatleva T, Sajjad A, Pogoryelov D, Patra C, Schermuly RT, Engel FB. FGF1-mediated cardiomyocyte cell cycle reentry depends on the interaction of FGFR-1 and Fn14. FASEB J. 2014;28:2492–503.PubMedCrossRefGoogle Scholar
  41. Ortiz A, Sanz AB, Muñoz García B, Moreno JA, Sánchez Niño MD, Martín-Ventura JL, Egido J, Blanco-Colio LM. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev. 2009;20:251–8.PubMedCrossRefGoogle Scholar
  42. Ortiz A, Husi H, Gonzalez-Lafuente L, Valiño-Rivas L, Fresno M, Sanz AB, Mullen W, Albalat A, Mezzano S, Vlahou T, et al. Mitogen-activated protein kinase 14 promotes AKI. J Am Soc Nephrol. 2017;28(3): 823–36.Google Scholar
  43. Purcell JW, Kim HK, Tanlimco SG, Doan M, Fox M, Lambert P, Chao DT, Sho M, Wilson KE, Starling GC, et al. Nuclear factor κB is required for tumor growth inhibition mediated by enavatuzumab (PDL192), a humanized monoclonal antibody to TweakR. Front Immunol. 2014;4:505.PubMedPubMedCentralCrossRefGoogle Scholar
  44. Rayego-Mateos S, Morgado-Pascual JL, Sanz AB, Ramos AM, Eguchi S, Batlle D, Pato J, Keri G, Egido J, Ortiz A, et al. TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation. J Pathol. 2013;231:480–94.PubMedCrossRefGoogle Scholar
  45. Ruiz-Andres O, Suarez-Alvarez B, Sánchez-Ramos C, Monsalve M, Sanchez-Niño MD, Ruiz-Ortega M, Egido J, Ortiz A, Sanz AB. The inflammatory cytokine TWEAK decreases PGC-1α expression and mitochondrial function in acute kidney injury. Kidney Int. 2016;89(2):399–410.Google Scholar
  46. Sanchez-Niño MD, Poveda J, Sanz AB, Mezzano S, Carrasco S, Fernandez-Fernandez B, Burkly LC, Nair V, Kretzler M, Hodgin JB, et al. Fn14 in podocytes and proteinuric kidney disease. Biochim Biophys Acta. 2013;1832:2232–43.PubMedCrossRefGoogle Scholar
  47. Sanz AB, Sanchez-Niño MD, Izquierdo MC, Jakubowski A, Justo P, Blanco-Colio LM, Ruiz-Ortega M, Egido J, Ortiz A. Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. J Cell Mol Med. 2009;13:3329–42.PubMedPubMedCentralCrossRefGoogle Scholar
  48. Sanz AB, Sanchez-Niño MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A. Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells. PLoS One. 2012;7:e47440.PubMedPubMedCentralCrossRefGoogle Scholar
  49. Sanz AB, Aroeira LS, Bellon T, del Peso G, Jimenez-Heffernan J, Santamaria B, Sanchez-Niño MD, Blanco-Colio LM, Lopez-Cabrera M, Ruiz-Ortega M, et al. TWEAK promotes peritoneal inflammation. PLoS One. 2014a;9:e90399.PubMedPubMedCentralCrossRefGoogle Scholar
  50. Sanz AB, Izquierdo MC, Sanchez-Niño MD, Ucero AC, Egido J, Ruiz-Ortega M, Ramos AM, Putterman C, Ortiz A. TWEAK and the progression of renal disease: clinical translation. Nephrol Dial Transplant. 2014b;29(Suppl 1):i54–62.PubMedPubMedCentralCrossRefGoogle Scholar
  51. Sanz AB, Ruiz-Andres O, Sanchez-Niño MD, Ruiz-Ortega M, Ramos AM, Ortiz A. Out of the TWEAKlight: elucidating the role of Fn14 and TWEAK in acute kidney injury. Semin Nephrol. 2016;36:189–98.PubMedCrossRefGoogle Scholar
  52. Sharif MN, Campanholle G, Nagiec EE, Wang J, Syed J, O’Neil SP, Zhan Y, Brenneman K, Homer B, Neubert H, et al. Soluble Fn14 is detected and elevated in mouse and human kidney disease. PLoS One. 2016;11:e0155368.PubMedPubMedCentralCrossRefGoogle Scholar
  53. Tajrishi MM, Sato S, Shin J, Zheng TS, Burkly LC, Kumar A. The TWEAK-Fn14 dyad is involved in age-associated pathological changes in skeletal muscle. Biochem Biophys Res Commun. 2014a;446:1219–24.PubMedPubMedCentralCrossRefGoogle Scholar
  54. Tajrishi MM, Shin J, Hetman M, Kumar A. DNA methyltransferase 3a and mitogen-activated protein kinase signaling regulate the expression of fibroblast growth factor-inducible 14 (Fn14) during denervation-induced skeletal muscle atrophy. J Biol Chem. 2014b;289:19985–99.PubMedPubMedCentralCrossRefGoogle Scholar
  55. Tajrishi MM, Zheng TS, Burkly LC, Kumar A. The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease. Cytokine Growth Factor Rev. 2014c;25:215–25.PubMedCrossRefGoogle Scholar
  56. Tarín C, Fernández-Laso V, Sastre C, Madrigal-Matute J, Gómez M, Zaragoza C, Egido J, Burkly LC, Martín-Ventura JL, Blanco-Colio LM. Tumor necrosis factor-like weak inducer of apoptosis or Fn14 deficiency reduce elastase perfusion-induced aortic abdominal aneurysm in mice. J Am Heart Assoc. 2014;3(11):pii e000723.Google Scholar
  57. Tirnitz-Parker JE, Viebahn CS, Jakubowski A, Klopcic BR, Olynyk JK, Yeoh GC, Knight B. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology. 2010;52:291–302.PubMedCrossRefGoogle Scholar
  58. Ucero AC, Benito-Martin A, Fuentes-Calvo I, Santamaria B, Blanco J, Lopez-Novoa JM, Ruiz-Ortega M, Egido J, Burkly LC, Martinez-Salgado C, et al. TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. Biochim Biophys Acta. 2013a;1832(10):1744–55.PubMedCrossRefGoogle Scholar
  59. Ucero AC, Berzal S, Ocaña-Salceda C, Sancho M, Orzáez M, Messeguer A, Ruiz-Ortega M, Egido J, Vicent MJ, Ortiz A, et al. A polymeric nanomedicine diminishes inflammatory events in renal tubular cells. PLoS One. 2013b;8:e51992.PubMedPubMedCentralCrossRefGoogle Scholar
  60. Valiño-Rivas L, Gonzalez-Lafuente L, Sanz AB, Ruiz-Ortega M, Ortiz A, Sanchez-Niño MD. Non-canonical NFκB activation promotes chemokine expression in podocytes. Sci Rep. 2016;6:28857.PubMedPubMedCentralCrossRefGoogle Scholar
  61. van Kuijk AW, Wijbrandts CA, Vinkenoog M, Zheng TS, Reedquist KA, Tak PP. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade. Ann Rheum Dis. 2010;69:301–4.PubMedCrossRefGoogle Scholar
  62. Wang S, Jiang W, Chen X, Zhang C, Li H, Hou W, Liu Z, McNutt MA, Lu F, Li G. Alpha-fetoprotein acts as a novel signal molecule and mediates transcription of Fn14 in human hepatocellular carcinoma. J Hepatol. 2012;57:322–9.PubMedCrossRefGoogle Scholar
  63. Wen J, Xia Y, Stock A, Michaelson JS, Burkly LC, Gulinello M, Putterman C. Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. J Autoimmun. 2013;43:44–54.PubMedPubMedCentralCrossRefGoogle Scholar
  64. Wen J, Doerner J, Weidenheim K, Xia Y, Stock A, Michaelson JS, Baruch K, Deczkowska A, Gulinello M, Schwartz M, et al. TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. J Autoimmun. 2015;60:40–50.PubMedPubMedCentralCrossRefGoogle Scholar
  65. Whitsett TG, Cheng E, Inge L, Asrani K, Jameson NM, Hostetter G, Weiss GJ, Kingsley CB, Loftus JC, Bremner R, et al. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol. 2012;181:111–20.PubMedPubMedCentralCrossRefGoogle Scholar
  66. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev. 2003;14:241–9.PubMedCrossRefGoogle Scholar
  67. Wilhelm A, Shepherd EL, Amatucci A, Munir M, Reynolds G, Humphreys E, Resheq Y, Adams DH, Hübscher S, Burkly LC, et al. Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation. J Pathol. 2016;239:109–21.PubMedPubMedCentralCrossRefGoogle Scholar
  68. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7:411–25.PubMedPubMedCentralCrossRefGoogle Scholar
  69. Wisniacki N, Amaravadi L, Galluppi GR, Zheng TS, Zhang R, Kong J, Burkly LC. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis. Clin Ther. 2013;35:1137–49.PubMedCrossRefGoogle Scholar
  70. Wu F, Guo L, Jakubowski A, Su L, Li WC, Bonner-Weir S, Burkly LC. TNF-like weak inducer of apoptosis (TWEAK) promotes beta cell neogenesis from pancreatic ductal epithelium in adult mice. PLoS One. 2013;8:e72132.PubMedPubMedCentralCrossRefGoogle Scholar
  71. Xia Y, Herlitz LC, Gindea S, Wen J, Pawar RD, Misharin A, Perlman H, Wu L, Wu P, Michaelson JS, et al. Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. J Am Soc Nephrol. 2014;26(5):1053–70.PubMedPubMedCentralCrossRefGoogle Scholar
  72. Yadava RS, Foff EP, Yu Q, Gladman JT, Kim YK, Bhatt KS, Thornton CA, Zheng TS, Mahadevan MS. TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy. Hum Mol Genet. 2015;24:2035–48.PubMedCrossRefGoogle Scholar
  73. Yin X, Luistro L, Zhong H, Smith M, Nevins T, Schostack K, Hilton H, Lin TA, Truitt T, Biondi D, et al. RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response. Clin Cancer Res. 2013;19:5686–98.PubMedCrossRefGoogle Scholar
  74. Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, Eisenberg RA, Michaelson JS, Putterman C. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol. 2007;179:7949–58.PubMedCrossRefGoogle Scholar
  75. Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB, Hittelman WN, et al. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol. 2013a;133:1052–62.PubMedCrossRefGoogle Scholar
  76. Zhou H, Hittelman WN, Yagita H, Cheung LH, Martin SS, Winkles JA, Rosenblum MG. Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. Cancer Res. 2013b;73:4439–50.PubMedPubMedCentralCrossRefGoogle Scholar
  77. Zhou H, Mohamedali KA, Gonzalez-Angulo AM, Cao Y, Migliorini M, Cheung LH, LoBello J, Lei X, Qi Y, Hittelman WN, et al. Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC. Mol Cancer Ther. 2014;13:2688–705.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Diego Martin-Sanchez
    • 1
  • Miguel Fontecha-Barriuso
    • 1
  • Maria D. Sanchez-Niño
    • 1
  • Maria C. Izquierdo
    • 2
  • Alvaro C. Ucero
    • 3
  • Alberto Ortiz
    • 1
  • Ana B. Sanz
    • 1
  1. 1.IIS-Fundacion Jimenez Diaz and Universidad Autonoma de MadridMadridSpain
  2. 2.Columbia University Medical CenterNew YorkUSA
  3. 3.Spanish National Cancer Research CenterMadridSpain